Compositions and methods of targeting mutant K-RAS
Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
1. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:
2,4-dimethyl-N-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(4-benzamidophenyl)thiazol-2-yl)-2,4-dimethylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2,4-dimethyl-N-(4-(2-oxochroman-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2-cyclopropyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-phenylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(1-acetyl-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2,4-dimethylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2,4-dimethyl-N-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-cyclopropyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-ethyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2,4-dimethyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-4-phenylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2,4-dimethyl-N-(5-methyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(5-ethyl-4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2,4-dimethylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2-(methoxymethyl)-4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2-cyclopropyl-4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-phenylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
N-(4-(1-benzyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2,4-dimethylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-(tetrahydrofuran-3-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-(pyridin-2-ylmethyl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
2-(1H-imidazol-1-yl)-4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof;
4-methyl-2-morpholino-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof; and
2-(2-methoxyethoxy)-4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
2. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound is 2-cyclopropyl-4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
3. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound is 4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-phenylthiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
4. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound is 4-methyl-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)-2-(tetrahydrofuran-3-yl)thiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound or pharmaceutically acceptable salt of claim 1 .
6. A compound according to Formula IV,
wherein R3 is selected from the group consisting of H, methyl, and halogen;
or a pharmaceutically acceptable salt of the compound of Formula IV.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound or pharmaceutically acceptable salt of claim 6 .